# US 2010/0137425 A1 · Inhibition and treatment of prostate cancer metastasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137425 A1
- Document ID: US20100137425A1
- Status: Published application
- Kind: A1
- Application number: 12/578,137
- Filed: 2009-10-13
- Published: 2010-06-03
- Earliest claimed: 2008-10-10
- Assignees: Northwestern University
- Inventors: Raymond C. Bergan; Karl A. Scheidt
- Web page: https://patentgrep.com/patent/US20100137425A1

## CPC

- C07D 311/38: 2,3-Dihydro derivatives, e.g. isoflavanones
- A61K 31/37: Coumarins, e.g. psoralen
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.

## Claims

### Claim 1

A method for inhibiting prostate cancer metastasis, comprising: administering a compound having formula:
to a subject having prostate cancer; wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 2 (depends on 1)

The method of claim 1, wherein, if Z is H, one of R7 or R8 is OH or OCH3.

### Claim 3 (depends on 1)

The method of claim 1, wherein R3, R4, R5, and R6 are each H.

### Claim 4 (depends on 1)

The method of claim 1, wherein Z is OCH3, halogen, or H.

### Claim 5 (depends on 1)

The method of claim 1, wherein Z is halogen.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound is:

### Claim 7 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound is administered prior to surgical removal of a tumor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is administered after surgical removal of a tumor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is co-administered with a different prostate cancer therapeutic agent.

### Claim 11

A pharmaceutical preparation comprising a compound having formula:
wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 12 (depends on 11)

The composition of claim 11, wherein, if Z is H, one of R7 or R8 is OH or OCH3.

### Claim 13 (depends on 11)

The composition of claim 11, wherein R3, R4, R5, and R6 are each H.

### Claim 14 (depends on 11)

The composition of claim 11, wherein Z is OCH3, halogen, or H.

### Claim 15 (depends on 11)

The composition of claim 11, wherein Z is halogen.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the compound is:

### Claim 17

A compound having the formula:

### Claim 18 (depends on 17)

A pharmaceutical composition comprising the compound of claim 17.

### Claim 19 (depends on 17)

A method for treating a subject comprising: administering the compound of claim 17 to a subject.

### Claim 20 (depends on 17)

Use of the compound of claim 17 for the treatment of prostate cancer.

### Claim 21 (depends on 17)

Use of the compound of claim 17 for the manufacture of a medicament for use in the treatment of prostate cancer.

### Claim 22

A compound having the formula:

### Claim 23 (depends on 22)

A pharmaceutical composition comprising the compound of claim 22.

### Claim 24 (depends on 22)

A method for treating a subject comprising: administering the compound of claim 22 to a subject.

### Claim 25 (depends on 22)

Use of the compound of claim 22 for the treatment of prostate cancer.

### Claim 26 (depends on 22)

Use of the compound of claim 22 for the manufacture of a medicament for use in the treatment of prostate cancer.

### Claim 27

A method for inhibiting prostate cancer metastasis in a subject, comprising activating the endoglin pathway in said subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein said activation results in increased expression of a gene selected from the group consisting of a gene encoding endoglin, a gene encoding ALK2, a gene encoding Smad1, and genes activated by Smad1.

### Claim 29 (depends on 27)

The method of claim 27, wherein said activation results in increased activity of a protein selected from the group consisting of endoglin, ALK2, and Smad1.

### Claim 30 (depends on 27)

The method of claim 27, wherein said activation is achieved through gene therapy.

### Claim 31 (depends on 27)

The method of claim 27, wherein said activation is achieved by administration of a small molecule.

### Claim 32 (depends on 27)

The method of claim 27, wherein said activation is achieved by administration of a compound having formula:
to the subject; wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 33 (depends on 27)

The method of claim 27, wherein said activation is achieved by administration of a compound selected from the group consisting of

### Claim 34

A method for preventing prostate cancer cell invasion in a subject, comprising:
administering a compound having formula:
to said subject; wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 35 (depends on 34)

The method of claim 34, wherein said subject has been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 36 (depends on 34)

The method of claim 34, wherein said subject has not been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 37 (depends on 34)

The method of claim 34, wherein said subject is at risk of developing prostatic intraepithelial neoplasmia.

### Claim 38

A method for preventing prostate cancer cell invasion in a subject, comprising:
administering a compound selected from the group consisting of

### Claim 39 (depends on 38)

The method of claim 38, wherein said subject has been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 40 (depends on 38)

The method of claim 38, wherein said subject has not been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 41 (depends on 38)

The method of claim 38, wherein said subject is at risk of developing prostatic intraepithelial neoplasmia.

### Claim 42

A method of preventing invasion of a prostate cell through the basement membrane into the prostate gland in a subject, comprising:
administering a compound having formula:
to said subject; wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 43 (depends on 42)

The method of claim 42, wherein said subject has been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 44 (depends on 42)

The method of claim 42, wherein said subject has not been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 45 (depends on 42)

The method of claim 42, wherein said subject is at risk of developing prostatic intraepithelial neoplasmia.

### Claim 46

A method of preventing invasion of a prostate cell through the basement membrane into the prostate gland in a subject, comprising:
administering a compound selected from the group consisting of

### Claim 47 (depends on 46)

The method of claim 46, wherein said subject has been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 48 (depends on 46)

The method of claim 46, wherein said subject has not been diagnosed with prostatic intraepithelial neoplasmia.

### Claim 49 (depends on 46)

The method of claim 46, wherein said subject is at risk of developing prostatic intraepithelial neoplasmia.

### Claim 50

A method for preventing prostate cancer in a subject, comprising:
administering a compound having formula:
to said subject; wherein A is O, C═O, CHOH, C═NR, or CH2; X is C═O, O or NH; Y is O, NH, CR9═CR10, or CH═N; Z is OH, OCH3, halogen, H provided that one of R7 or R8 is OH or OCH3, or OCO wherein Z forms a heterocyclic group with the carbon at position R10; the dashed line represents an optional double bond; R is H or a substituted or unsubstituted alkyl group; R1 is selected from the group consisting of H and substituted or unsubstituted alkyl groups; R2 is selected from the group consisting of H, OH, F and Cl; or is absent when the optional double bond is present; R3, R4, R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of OH, F, Cl, Br, I, CN, NO2, COOR, CONH2, and substituted and unsubstituted alkyl and alkoxy groups; wherein said compound is not genistein.

### Claim 51

A method of preventing prostate cancer in a subject, comprising:
administering a compound selected from the group consisting of
